SNDXSyndax Pharmaceuticals, Inc.
$16.99+15% 1Y
$16.99
$13.1152 weeks$25.15
The financials
Syndax Pharmaceuticals, Inc. by the numbers
Syndax Pharmaceuticals, Inc. (SNDX) reported revenue of $73M in Q2 2026 (quarter ended Jun 30, 2026), up 92% from the same quarter a year earlier. That came with net loss of $49M. For the full year FY2025, revenue was $172M (+628% year on year) and net income −$285M. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $73M | $38M | +92% |
| Operating income | −$40M | −$69M | n/a |
| Net income | −$49M | −$72M | n/a |
| Diluted EPS | −$0.55 | −$0.83 | n/a |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $18.1M (+13%)
Collaboration grew +93% year on year
Segment Latestquarter on quarteryear on year
- Collaboration$18.1M$18.1Mquarter on quarter +13%year on year +93%+13%+93%